Steven Brem, MD - Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024. Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc. Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity. Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC. Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics. Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.